Universite Claude Bernard – Lyon1

Nanoh

Centre National De La Recherche Scientifique

Nh Theraguix

Universitë De Bordeaux

Université Grenoble Alpes

Institut National Des Sciences Appliquees De Lyon

Université Claude Bernard Lyon I

The Brigham and Women's Hospital, Inc.

Centre National De La Recherche Gantifote—cnrs—

Institut National De La Sante Et De La Recherche Medicale

Ecole Nationale Superieure De Chimie De Paris

Université Lyon 1 Claude Bernard

Université De Paris 5 René Descartes

Mexbrain

François Lux

Olivier Tillement

Stéphane Roux

Jean-Luc Coll

Nathalie Mignet

Pascal Perriat

Fabien Rossetti

Anna Mignot

Pierre Mowat

Andrea Bianchi

Sandrine Dufort

Maxime Saint Jean

Ross Berbeco

Johanne Seguin

Yannick Cremillieux

Vivek Thakare

Myleva Dahan

Vu-Long Tran

Clélia Mathieu

Geraldine Le Duc

Alexandre Detappe

Eloise Thomas

Vu Long Tran

Grégory Ramniceanu

Bich-Thuy Doan

Marie Victor

Denise Bechet

Jules Tillement

Lucie Sancey Galliot

The present invention relates to the field of nanovectors for the delivery of active substances in the body, in particular for the treatment of tumours. In particular, the use of these nanovectors makes it possible to improve the pharmacokinetics of the active substances with a more selective delivery, for example in the tumour tissues.

Nanovectors and uses

Provided herein are nanoparticle compositions (e.g., nanoparticle compositions comprising high atomic number ions) that are useful for imaging diseases in a subject as well as radiosensitizing a disease in a subject (e.g., radiosensitizing a cancer in the subject). Methods of imaging a subject, methods of treating cancer, and processes of preparing the nanoparticle compositions are also provided.

Bismuth-gadolinium nanoparticles

The invention relates to a novel use of ultrafine nanoparticles, of use as a diagnostic, therapeutic or theranostic agent, characterized by their mode of administration via the airways. The invention is also directed toward the applications which follow from this novel mode of administration, in particular for imaging the lungs, and the diagnosis or prognosis of pathological pulmonary conditions. In the therapeutic field, the applications envisioned are those of radiosensitizing or radioactive agents for radiotherapy (and optionally curietherapy), or for neutron therapy, or of agents for PDT (photodynamic therapy), in particular for the treatment of lung tumors.

Ultrafine nanoparticles as multimodal contrast agent

The invention relates to a method for synthesizing ultrasmall silica nanoparticles, useful in particular for diagnostics and/or therapy. More specifically, a method for synthesizing silica nanoparticles, said method comprising the mixing of at least one silane which is negatively charged at physiological pH with at least one silane which is neutral at physiological pH, and/or at least one silane which is positively charged at physiological pH, wherein: &#x2014;the molar ratio A of neutral silane(s) to negatively charged silane(s) is defined as follows: 0&#x2264;A&#x2264;6, &#x2014;the molar ratio B of positively charged silane(s) to negatively charged silane(s) is defined as follows: 0&#x2264;B&#x2264;5, &#x2014;the molar ratio C of neutral and positively charged silanes to negatively charged silane(s) is defined as follows: 0&#x3c;C&#x2264;8. The invention also relates to the obtained ultrasmall silica nanoparticles.

Method for synthesizing silica nanoparticles

The invention relates to novel biocompatible hybrid nanoparticles of very small size, useful in particular for diagnostics and/or therapy. The purpose of the invention is to offer novel nanoparticles which are useful in particular as contrast agents in imaging (e.g. MRI) and/or in other diagnostic techniques and/or as therapeutic agents, which give better performance than the known nanoparticles of the same type and which combine both a small size (for example less than 20 nm) and a high loading with metals (e.g. rare earths), in particular so as to have, in imaging (e.g. MRI), strong intensification and a correct response (increased relaxivity) at high frequencies. Thus, the nanoparticles according to the invention, with diameter dbetween 1 and 20 nm, each comprise a polyorganosiloxane (POS) matrix including gadolinium cations optionally associated with doping cations; a chelating graft CDTPABA (diethylenetriaminepentaacetic acid bisanhydride) bound to the POS matrix by an &#x2014;Si&#x2014;C&#x2014; covalent bond, and present in sufficient quantity to be able to complex all the gadolinium cations; and optionally another functionalizing graft Gf* bound to the POS matrix by an &#x2014;Si&#x2014;C&#x2014; covalent bond (where Gf* can be derived from a hydrophilic compound (PEG); from a compound having an active ingredient PA1; from a targeting compound; from a luminescent compound (fluorescein). The method for the production of these nanoparticles and the applications thereof in imaging and in therapy also form part of the invention.

Ultrafine nanoparticles comprising a functionalized polyorganosiloxane matrix and including metal complexes; method for obtaining same and uses thereof in medical imaging and/or therapy

The invention relates to novel biocompatible hybrid nanoparticles of very small size, useful in particular for diagnostics and/or therapy. The purpose of the invention is to offer novel nanoparticles which are useful in particular as contrast agents in imaging (e.g. MRI) and/or in other diagnostic techniques and/or as therapeutic agents, which give better performance than the known nanoparticles of the same type and which combine both a small size (for example less than 20 nm) and a high loading with metals (e.g. rare earths), in particular so as to have, in imaging (e.g. MRI), strong intensification and a correct response (increased relaxivity) at high frequencies. The method for the production of these nanoparticles and the applications thereof in imaging and in therapy also form part of the invention.

Growing community of inventors

Lyons, France

François Lux